Kexin Biotech's First Distributor Annual Meeting in 2015 Grandly Held
Release time：2015.11.04
In the crisp golden autumn with the fragrance of osmanthus, Shanghai Kexin Biotechnology Co., Ltd. held its first "Technological Innovation, Win-Win Future" distributors' annual meeting as scheduled on October 24, 2015, at the Evergreen Laurel Hotel in Shanghai. Distributors from all over the country gathered to listen to our company's strategic planning, latest R&D updates, product sales strategies, and sales policies, jointly discussing the current status of the diagnostic reagent industry and seeking ways for development. 。
On the morning of the 24th, the distributors' annual meeting was opened under the hosting of Mr. Lu Yang, the company's Deputy General Manager.
The meeting began with a welcome speech by Mr. Bao Jun, Chairman and General Manager of Kexin Group, who gave a keynote speech on the company culture, development history, and future development strategy of Kexin Biotechnology Group. Mr. Bao reviewed the growth of Kexin Biotechnology from nothing to a large company, emphasizing the need to improve governance structure, insist on independent R&D, enhance market insight and innovation capabilities, strengthen the market output of innovative products, and provide a broader win-win platform for distributors.
Professor Zhu Daocheng, the company's Chief Scientist, introduced the existing technology platforms, products under development, and future product R&D strategies to the distributors present. Good products are the foundation of all marketing, and Kexin's strong scientific research strength is the basis of good products as well as a strong backing for effective marketing.
Mr. Chen Jiulong, Marketing Director, gave a detailed introduction to the clinical significance and advantages of the company's existing products, analyzed the current market situation, the upgrade plan for mature existing products, and the plan for launching new products in the future. This allowed distributor partners to see the market development prospects and advantages of Kexin products, pointing out the market direction for everyone.
Ms. Xu Yongling, Sales Director, stated that distributor partners are the backbone of Kexin's sales. We must maintain close contact, cooperate for mutual benefit, and grow stronger. She focused on policies regarding distributor incentives and support, which attracted the distributors with Kexin's distinctive policies and profit margins.
On the 25th, the company invited Researcher Li Yongzhe from the Rheumatology and Immunology Department of Peking Union Medical College Hospital, who is a member of the Clinical Immunology Expert Committee of the Chinese Medical Association's Laboratory Medicine Branch, a member of the Clinical Immunology Branch of the Chinese Immunology Society, a peer reviewer for the National Natural Science Foundation, and an expert reviewer for the Ministry of Science and Technology's 863 Program. He gave a report titled "Current Status and Progress of Diagnostic Markers for Rheumatic Immune Diseases." After the report, active discussions on related topics took place among the attendees.
During the meeting, company leaders at all levels closely communicated with distributor friends and Professor Li Yongzhe about the market status and prospects of new diagnostic reagents, while also answering questions about the company's upcoming new products. Kexin adheres to the philosophy of "Creating value through technology, leading the future through innovation, establishing trust through quality, and contributing to public health." In the highly competitive market of new diagnostic reagent products dominated by foreign manufacturers, Kexin has earned a place for the state-owned independent brand and gained recognition from many distributors.
The successful conclusion of this distributors' annual meeting is only the starting point of sincere cooperation between Kexin and its distributor partners. Now and in the future, Kexin will maintain close contact with distributor partners and work together to make positive contributions to the continuous development of human life sciences!
Copyright © 2025 Beijing Kinghawk Pharmaceutical Co., Ltd. All rights reserved.